Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

NCT01461538 is registered in ClinicalTrials.gov with Seagen Inc. as lead sponsor.

NCT NCT01461538
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01461538 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Lead sponsor
Seagen Inc.
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2011
Completion date
December 31, 2014
Enrollment
84 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoid leukemia, acute myeloid leukemia, anemia, refractory, with excess of blasts, solid tumors